Exhibit 12

	For the Year Ended
	December 31, 2005		December 25, 2004		December 27, 2003		December 28, 2002	December 20, 2001
Fixed charges
Interest expense	3,098		2,199		1,350		2,130	2,128
Interest capitalized	106		326		83		—	5,202
Capitalized expenses related to indebtedness	—		—		—		—	—
Estimate of interest within rental expense	183		156		149		218	422
Preference security dividend	—		—		—		—	—
Total fixed charges	3,387		2,681		1,582		2,348	7,752
Earnings
Pretax income from continuing operations	(129,872	)	(39,992	)	(12,215	)	1,738	115,769
Fixed charges	3,387		2,681		1,582		2,348	7,752
Amortization of capitalized interest	1,277		1,266		1,273		1,274	148
Interest capitalized	(106	)	(326	)	(83	)	—	(5,202	)
Total earnings	(125,314	)	(36,371	)	(9,443	)	5,360	118,467
Ratio
Adjusted Earnings	(125,314	)	(36,371	)	(9,443	)	5,360	118,467
Total Fixed charges	3,387		2,681		1,582		2,348	7,752
Ratio of Earnings to fixed charges	N/A		N/A		N/A		2.3	15.3

For the years ended December 27, 2003, December 25, 2004 and December 31, 2005, Nabi Biopharmaceuticals did not generate sufficient earnings to cover its fixed charges by the following amounts:

	For the Year Ended
Dollar amounts in thousands	Dec. 31, 2005		Dec. 25, 2004		Dec. 27, 2003		Dec. 28, 2002	Dec. 29, 2001
Coverage deficiency	$	128,701	$	39,052	$	11,025	N/A	N/A